|
NEWS RELEASE
8th June 2022
THE LANCET HEALTHY LONGEVITY: Little evidence testosterone treatment increases the risk of cardiovascular events, most in-depth analysis suggests
THE LANCET
- Meta-analysis of data from more than 3,400 patients with hypogonadism from 17 clinical trials finds little evidence that testosterone treatment increases the risk of cardiovascular events such as arrhythmia, heart attack, and stroke, in the short-to-medium term.
- The rate of cardiovascular events was not significantly higher for participants receiving testosterone treatment (120/1,601 [7·5%]) compared to placebo (110/1,519 [7·2%]). Fewer deaths were reported during testosterone (6/1,621 deaths, [0·4%]) than placebo (12/1,537 deaths, [0·8%]), but numbers were too small to establish whether testosterone reduced mortality risk.
- The authors say that while longer-termanalysis of cardiovascular safety is required, the findings should reassure men with hypogonadism worldwide about the short-to-medium safety of testosterone.
Testosterone replacement therapy appears safe in the short-to-medium term to treat a condition caused by deficiency of the male sex hormone, according to the most comprehensive analysis of the treatment to date, published in The Lancet Healthy Longevity journal.
The findings suggest that men given testosterone to treat hypogonadism are at no greater risk of heart attack, stroke, and other cardiovascular events in the short-to-medium term than men who do not receive testosterone treatment.
Testosterone replacement therapy is the standard treatment for hypogonadism, which can cause sexual dysfunction, weakening of bones and muscles, and reduced quality of life. Risk factors for the condition include aging (as testosterone levels decline with age), obesity (BMI of 30 kg/m2 or above), and diabetes.
Despite being widely used, the cardiovascular safety of testosterone treatment has until now remained unclear due to inconsistent findings. This is because most previous clinical studies have relied on aggregate data, rather than individual participant data and have not published details of individual adverse events.
Lead author, Jemma Hudson from the University of Aberdeen, explains: “Prescribing of testosterone for hypogonadism is increasing globally, but conflicting messages about its safety may have led to many patients not receiving the treatment. Ongoing studies should help to determine the longer-term safety of testosterone but, in the meantime, our results provide much-needed reassurance about its short-to-medium term safety. Our findings could have important implications for the treatment of men with hypogonadism worldwide.” [1]
The authors conducted a systematic review identifying 35 eligible clinical trials published since 1992, of which 17 provided individual participant data. A blinded analysis by two independent clinicians enabled the classification of every cardiovascular event, allowing for a more robust analysis of the cardiovascular safety of testosterone treatment. A meta-analysis using individual participant data from 17 studies and a further meta-analysis integrating these data with the aggregate data provided by the 18 trials that did not provide individual participant data were performed.
Among the 17 trials with individual patient data, 1,750 participants received testosterone and 1,681 were given a placebo. The average length of testosterone treatment was 9.5 months. The average age of participants was 65 years, and most were white and did not smoke. Participants’ average BMI was 30 kg/m2, which is considered obese.
A meta-analysis showed there were 120/1,601 (7.5%) cardiovascular events in the testosterone group and 110/1,519 (7.2%) in the placebo group across 13 trials that provided this information. Patient age, smoking or diabetes status did not affect cardiovascular risk. Similarly, there was no significant difference in mortality rate between the testosterone group (6/1,621 deaths, 0.4%) and the placebo group (12/1,537 deaths, 0.8%) across the 14 trials that provided individual patient data on mortality, but only limited data were available.
The researchers also found that testosterone significantly reduced serum total cholesterol, high-density lipoprotein (HDL), and triglycerides compared with placebo. However, there were no significant differences in serum low-density lipoprotein (LDL), blood pressure, glycaemic parameters, diabetes incidence, and prostate adverse outcomes between the testosterone and placebo groups.
The meta-analysis that integrated individual participant data with aggregate data showed similar results.
The authors acknowledge some limitations to their study. There was little available data evaluating the cardiovascular safety of testosterone treatment beyond 12 months, and the very small number of deaths recorded during testosterone trials hampered the authors’ ability to analyse why they occurred. However, the longer-term safety of testosterone treatment is currently being investigated in another clinical trial. While the meta-analysis of aggregate data showed similar results to the one involving individual patient data only, it cannot be ruled out with certainty that a high number of unreported cardiovascular events in the trials that did not provide individual participant data could alter the current conclusions.
NOTES TO EDITORS
These findings will be also presented on Monday 13 June at 11:00 am ET at ENDO 2022, the Endocrine Society’s annual meeting: https://endo2022.endocrine.org/
This study was funded by the UK NIHR Health Technology Assessment Programme. It was led by researchers from University of Aberdeen and Imperial College London in collaboration with University of Newcastle-on-Tyne, Harvard Medical School, University of Pennsylvania, University of Melbourne, Fiona Stanley Hospital, Utrecht University, Leiden University, Aston University, University Hospitals Birmingham, University Hospital of North Norway, University of Norway, University of Colorado, University of Ljubljana, Western University and Omega Fertility Center, VA Palo Alto Health Care System, Stanford University, University of Malaya, Taylor's University, Malaysia, University College London, UCLA, University of Sheffield, University of Manchester, and University of Southern Denmark.
[1] Quote direct from author and cannot be found in the text of the Article.
The labels have been added to this press release as part of a project run by the Academy of Medical Sciences seeking to improve the communication of evidence. For more information, please see: http://www.sciencemediacentre.org/wp-content/uploads/2018/01/AMS-press-release-labelling-system-GUIDANCE.pdf if you have any questions or feedback, please contact The Lancet press office pressoffice@lancet.com
For interviews with the Article author, please contact: E) Dr Channa Jayasena c.jayasena@imperial.ac.uk T) +44 07799400094
For embargoed access to the Article, please see: http://www.thelancet-press.com/embargo/TRT.pdf
For embargoed access to the Appendix, please see: http://www.thelancet-press.com/embargo/TRTAPPX.pdf
NOTE: THE ABOVE LINKs ARE FOR JOURNALISTS ONLY; IF YOU WISH TO PROVIDE A LINK FOR YOUR READERS, PLEASE USE THE FOLLOWING, WHICH WILL GO LIVE AT THE TIME THE EMBARGO LIFTS: http://www.thelancet.com/journals/lanhl/article/PIIS2666-7568(22)00096-4/fulltext
Contact The Lancet press office:
LONDON
Thea Elvin, Press Officer
Tel: +44 (0) 7584 545719
thea.elvin@lancet.com
USA
Johanna Harvey, Media and Communications Manager, North America
Tel: +1 267-515-1767
johanna.harvey@lancet.com
OUTSIDE OF UK HOURS
Tel: +44 (0) 207 424 4249
Media Contact
The Lancet Press Office
The Lancet
pressoffice@lancet.com
Office: +44 (0) 207 424 4249
The Lancet,
Elsevier Limited,
Kidlington, Oxford,
United Kingdom, OX5 1GB
Source:
"Reproduced with permission - "The Lancet"
The Lancet
For more HIV and AIDS News visit...
Positively Positive - Living with HIV/AIDS:
HIV/AIDS News |
